Danaher reported second quarter revenues of $5.94 billion, up 4% year-over-year, driven primarily by robust growth in its bioprocessing division despite challenges in China’s diagnostics business. The company continues to navigate adverse impacts of China’s volume-based procurement programs and U.S.-China trade tariffs, with expectations unchanged for these headwinds. Core revenue growth was modest, with life sciences and diagnostics segments showing mixed performance. Danaher also announced CFO Matthew McGrew's upcoming retirement and named his successor effective February 2026.